#United States #North Stonington #Solace Nutrition #Encala #Structured Lipid

Solace Nutrition Unveils Critical Updates on Encala®

Introduction

Solace Nutrition, a prominent entity in the specialized field of clinical nutrition and medical foods, has made notable strides with its flagship product, Encala®. Initially relaunched in February 2025, Encala® is a structured-lipid medical food particularly tailored for those suffering from fat malabsorption, deficiencies in fatty acids and choline, and related growth issues in children and unintentional weight loss in adults. The company recently shared compelling clinical, scientific, and commercial updates about Encala® that indicate promising growth and progress in patient care.

Growth and Recognition

Since its reintroduction, Encala® has surpassed sales expectations, receiving recognition from healthcare providers familiar with its previous distribution through Envara Health, Inc. These providers highlight the product’s effectiveness in promoting weight gain and alleviating gastrointestinal symptoms associated with malabsorption disorders. Thomas Clough, the CEO of Solace Nutrition, noted, "Our dedicated in-house manufacturing, tailored patient support, and insurance assistance services have positioned us ideally to cater to the rising demand from patients facing diverse malabsorption conditions."

Targeted Patient Populations

Currently, Encala® is being utilized among patients with various health challenges, including pancreatic and intestinal diseases and short bowel syndrome. Solace Nutrition is not only focusing on domestic markets but is also planning to expand the availability of Encala® internationally. A Canadian launch is anticipated in the latter half of 2026, while South American expansion is targeted to occur by the end of the year. Specific populations that will benefit include patients with cystic fibrosis, rare pancreatic diseases, and individuals requiring enteral nutrition support in ICU settings.

Clinical Foundation and Legacy

Encala® is built upon a rich history of rigorous scientific research. The current formulation was backed by a highly encouraging outcome from a large NIH-funded randomized clinical trial that sought to measure nutritional outcomes in children with cystic fibrosis. Conducted by renowned pediatric nutritionist Dr. Virginia Stallings and her team, the trial revealed significant improvements in the growth and nutritional status of 110 participants.

This substantial investment, exceeding $17 million, covered research and development, including establishing a reimbursement code essential for enhancing patient access to Encala®. Structured Lipid Nutrition, LLC was created to safeguard this technology and subsequently formed a partnership with Solace Nutrition focusing on high-quality manufacturing and distribution.

Pioneering Research Updates

Solace Nutrition has also been proactive in launching research initiatives that expand the understanding and application of Encala® in clinical settings:

• - Pancreatic Cancer Study: Launched in September 2025, this study at the University of Pennsylvania aims to evaluate the impact of Encala® on gastrointestinal symptoms and quality of life for individuals diagnosed with specific pancreatic tumors.
• - Cerebral Palsy Research: A potential study is in the planning stages to assess the nutritional effects of Encala® on children and adults with moderate to severe cerebral palsy.
• - Innovations in Drug Delivery: Research supports Encala’s structured-lipid technology as a means to enhance the absorption of lipid-soluble medications, which opens pathways for future drug development.
• - Veterinary Nutrition: Positive outcomes have emerged from studies involving malnourished dogs and palatability assessments in cats, confirming the product's suitability across species.

Future Outlook

With a solid clinical foundation and innovative research backing it, Solace Nutrition is set to enhance the lives of those dealing with complex nutritional needs through Encala® and its growing suite of products. The commitment to improving access to effective nutritional solutions reaffirms Solace Nutrition's role as a trusted leader in medical nutrition.

For additional information on Encala® and its latest developments, healthcare providers and interested parties can reach out to Solace Nutrition directly.

Conclusion

In summary, Encala® has evolved through significant research and development efforts, and its promising updates reflect a strong future in clinical nutrition tailored for individuals with specific metabolic needs. As Solace Nutrition continues to innovate and expand, the potential for positive health outcomes in patients facing malabsorption challenges is immense.